# Vertex Pharmaceuticals

> Vertex discovers, develops and sells prescription medicines, led by its cystic fibrosis portfolio. Its business now spans gene-edited cell therapy for blood disorders, non-opioid acute pain treatment and, following the 2026 Crinetics acquisition, endocrine disease medicines.

- **Founded:** 1989
- **Headquarters:** Boston, United States
- **Founders:** Joshua Boger (Co-founder; former CEO), Kevin J. Kinsella (Co-founder; venture investor)
- **Products:** Kalydeco (ivacaftor), Orkambi (lumacaftor/ivacaftor), Symdeko / Symkevi (tezacaftor/ivacaftor), Trikafta / Kaftrio, Alyftrek
- **Notable:** FDA approval of Kalydeco in 2012 established treatment of CF’s underlying protein defect., Trikafta gained initial FDA approval in 2019., Casgevy became the first FDA-approved CRISPR-based treatment in December 2023.

## Products & services

- **Kalydeco (ivacaftor)** — CFTR potentiator for eligible people with cystic fibrosis; first U.S. approval in 2012.
- **Orkambi (lumacaftor/ivacaftor)** — CFTR modulator combination for eligible patients with cystic fibrosis.
- **Symdeko / Symkevi (tezacaftor/ivacaftor)** — CFTR modulator combination; brand and eligibility vary by market.
- **Trikafta / Kaftrio** — Elexacaftor/tezacaftor/ivacaftor combination for eligible CF patients; first U.S. approval in 2019.
- **Alyftrek** — Once-daily vanzacaftor/tezacaftor/deutivacaftor CFTR modulator combination; first FDA approval in 2024.
- **Casgevy (exagamglogene autotemcel)** — Autologous CRISPR-edited blood stem cell treatment developed with CRISPR Therapeutics for eligible patients with sickle cell disease or transfusion-dependent beta thalassemia. U.S. sickle cell approval in 2023, beta thalassemia approval in 2024; pediatric expansion in 2026.
- **Journavx (suzetrigine)** — Oral non-opioid NaV1.8 inhibitor approved by the FDA for moderate-to-severe acute pain in adults.
- **Palsonify (paltusotine)** — Once-daily oral acromegaly medicine added through the completed Crinetics acquisition in September 2026.
- **Vertex GPS and Vertex Connects** — U.S. patient support programs for eligible people prescribed CF medicines or gene therapy; enrollment conditions apply.

## Achievements

- FDA approval of Kalydeco in 2012 established treatment of CF’s underlying protein defect.
- Trikafta gained initial FDA approval in 2019.
- Casgevy became the first FDA-approved CRISPR-based treatment in December 2023.
- Journavx gained FDA approval in January 2025.
- Fiscal 2025 revenue reached approximately $12.0 billion.

## Latest updates

- **2026-10** — October 9: Vertex announced interim Alyftrek extension-study data in children ages 2 to 5, including recovery of pancreatic function in some participants; findings are study-specific.
- **2026-09** — September 22: Vertex reported Phase 2b AMPLIFIED inaxaplin results and completed enrollment in Phase 2/3 AMPLITUDE; inaxaplin remains investigational.
- **2026-09** — September 1: Vertex completed its Crinetics acquisition at an announced total equity value of approximately $10.0 billion.
- **2026-08** — August 3: reported Q2 revenue of $3.33 billion and raised 2026 revenue guidance to $13.1-$13.2 billion; this guidance excluded the then-pending Crinetics acquisition.

## Links

- Website: https://www.vrtx.com/
- LinkedIn: https://www.linkedin.com/company/vertex-pharmaceuticals/
- Twitter/X: https://x.com/VertexPharma
- YouTube: https://www.youtube.com/channel/UCrNu_QIE9exwVQnWKgr1toQ
- Instagram: https://www.instagram.com/vertexpharmaceuticals/
- Facebook: https://www.facebook.com/VertexPharmaInc

---

Profile page: https://yespress.io/vertex-pharmaceuticals
Published by YesPress — https://yespress.io
Last updated: 2026-10-22